



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service



Food and Drug Administration
Rockville MD 20857

DEC 16 1998

Re: Lotemax™/Alrex™
Docket No. 98E-0789

Stephen G. Kunin
Deputy Assistant Commissioner for
Patent Policy and Projects
U.S. Patent and Trademark Office
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,996,335 filed by Nicholas S. Bodor under 35 U.S.C. § 156. The human drug product claimed by the patent is Lotemax™/Alrex™ (loteprednol etabonate), which was assigned new drug application (NDA) No. 20-583.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1), and interpreted by the courts in Glaxo Operations UK Ltd. v. Quigg, 706 F. Supp. 1224 (E.D. Va. 1989), aff'd, 894 F.2d 392 (Fed. Cir. 1990).

The NDA was approved on March 9, 1998, which makes the submission of the patent term extension application on May 6, 1998, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,


(for) Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs

cc: Norman H. Stepno, Esq.
Burns, Doane, Swecker & Mathis LLP
P.O. Box 1404
Alexandria, VA 22313-1404